ARE YOU A SUBSCRIBER? LOG IN HERE TO ACCESS FULL ISSUES AND ARTICLES
OCTOBER 16, 2017 ANNOUNCEMENT: INDIVIDUAL ARTICLE ACCESS NOW AVAILABLE FOR OUR SUBSCRIBERS: Ask Us for Details!
ALSO SEE: Updated Coverage by Topic Page
Table of Contents – The MedTech Strategist, Vol. 4, No. 13, September 18, 2017 (44 Pages; Purchase this Full Issue):
- Perspective—“Silicon Valley Dollars ‘Up the Ante’ in Molecular Diagnostics,” by Wendy Diller
- MedTech in India—“Meril Life Sciences: Building a Global Medtech Business from India,” by David Cassak
- Orthopedics—“As HHS Shifts Policy, Early Evidence Is In: Bundled Payments Work in TJA,” by Wendy Diller
- China Strategies—“Is the China Window Closing?” by Dr. Yuval Binur, Contributor
- Start-Ups To Watch—“Interscope Medical: Bringing Precision to Gastrointestinal Resections,” by Mary Stuart
- Start-Ups To Watch—“Cagent Vascular: A New Angioplasty Balloon for Today’s Peripheral Artery Disease Patients,” by Mary Stuart
The entrance of non-traditional financing sources into clinical diagnostics has the potential to heat up a field that is already brimming with innovation, but also may distort valuations if the industry does not address business model and regulatory questions.
Atomwise—Cofactor Genomics—Color Genomics—Freenome—Genomic Health Inc.—Gingko Bioworks—Grail—Guardant Health—Neurotrack
MedTech in India
Meril Life Sciences: Building a Global Medtech Business from India
By David Cassak
With its billion-plus population, growing economy, and under-powered national medtech industry, India seems like a natural place to grow a major medical device company. Stepping into the breach is Meril Life Sciences. Founded by a family of entrepreneurs who had achieved success in agrochemicals and printing inks, Meril has made remarkable progress in its ten years in operation, with more than 100 products currently on the market. Now one of India’s largest native medtech companies, Meril’s ambitions are to create not just a major Indian medtech company, but a global company as well.
Abbott Vascular—Johnson & Johnson—Meril Life Sciences Pvt. Ltd.
As HHS Shifts Policy, Early Evidence Is In: Bundled Payments Work In TJA
By Wendy Diller
Orthopedics companies have redefined their customer base and re-set their business propositions in response to the growth of CMS-initiated bundled payment programs. After HHS announced in August that it is easing some bundle requirements, experts weigh in on the evidence of the impact to date of such programs on value-based medicine, and what’s in it for companies.
Is the China Window Closing?
By Dr. Yuval Binur, Contributor
Chinese VCs have turned away from massive, opportunistic investments overseas and are now more focused on building domestic platforms and in-licensing selected technologies and products. The upshot? While there are still considerable opportunities for medtech companies in China, they must understand and adapt to these changing trends. No longer can companies that fail to raise funds in the “old world” go on a road show to Beijing, Shanghai, or Shenzhen and return home with big dollar checks. The path to China and its potentially large market now lies in more collaborative efforts.
Start-Ups To Watch
Interscope Medical: Bringing Precision to Gastrointestinal Resections
By Mary Stuart
With a mechanical cutting instrument designed for flexible endoscopy, Interscope aims to offer a procedure that enables physicians to ensure a resection is complete, the first time around.
Start-Ups To Watch
Cagent Vascular: A New Angioplasty Balloon for Today’s Peripheral Artery Disease Patients
By Mary Stuart
Cagent Vascular has developed a balloon that uses serration technology to prepare the artery in a more controlled and less traumatic way than conventional balloon angioplasty. The company sees large markets in vessel preparation for above-the-knee applications, and is developing a limb-saving therapy for below-the-knee disease, where there are fewer durable treatment options.
Cagent Vascular—Intact Vascular